Zogenix stock soars after epilepsy test success

Share this post

(Reuters) – Zogenix Inc’s experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, putting it on track to request regulatory approval next year and more than tripling the value of its shares.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply